Impact of Delayed Chemotherapy Cycles on Remission Rates in Pediatric Sarcoma Patients
DOI:
https://doi.org/10.54112/bcsrj.v6i6.1890Keywords:
Pediatric sarcoma, Ewing sarcoma, osteosarcoma, chemotherapy delay, remission rate, dose intensityAbstract
Pediatric sarcomas, particularly Ewing sarcoma and osteosarcoma, are aggressive malignancies that require timely, protocol-based chemotherapy to maximize remission potential. Objective: To evaluate the effect of delayed chemotherapy cycles on remission rates in pediatric patients with Ewing sarcoma and osteosarcoma. Methods: This retrospective observational study was conducted at Shaukat Khanum Memorial Cancer Hospital and Research Center from 2023 to 2024. It included 150 pediatric patients (78 Ewing sarcoma, 72 osteosarcoma). A delayed cycle was defined as any cycle administered more than three days beyond the scheduled protocol date. Data on demographics, tumor type, delay causes, relative dose intensity (RDI), and remission status were collected from medical records. Results: Delays occurred in 92 patients (61.3%), most commonly due to hematologic toxicity (46.7%) and infections (30.4%). Overall remission rates were significantly higher in patients without delays (84.5%) compared to those with delays (58.7%, p = 0.001). In Ewing sarcoma, remission decreased from 79.4% in the no-delay group to 56.8% in the delayed group (p = 0.032), while in osteosarcoma, remission dropped from 91.7% to 60.4% (p = 0.004). Mean RDI was significantly lower in delayed patients (78.6% ± 8.9) versus on-time patients (93.4% ± 5.2, p < 0.001). Conclusion: Delayed chemotherapy cycles are associated with a significant reduction in remission rates in pediatric Ewing sarcoma and osteosarcoma, largely due to reduced dose intensity. Preventing delays through optimized supportive care and addressing logistical barriers should be prioritized to improve treatment outcomes.
Downloads
References
Zhang J, Huang Y, Sun Y, He A, Zhou Y, Hu H, Yao Y, Shen Z. Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience. BMC Cancer. 2019 Dec 2;19(1):1168. https://doi.org/10.1186/s12885-019-6407-5
Izubuchi Y, Nakajima H, Honjoh K, Imamura Y, Nojima T, Matsumine A. Primary intradural extramedullary Ewing sarcoma: A case report and literature review. Oncol Lett. 2020 Sep;20(3):2347-2355. https://doi.org/10.3892/ol.2020.11786
Klingberg D, Bae S, Zhou DD, Sim HW, Cai R, Anazodo A, Grimison P, Lewis C, Lee YC. Association of chemotherapy dose intensity and age with outcomes in patients with Ewing's family sarcoma. Asia Pac J Clin Oncol. 2025 Feb;21(1):87-94. https://doi.org/10.1111/ajco.13998
Kalaci E, Köksoy EB, Akbiyik I, Dursun B, Utkan G. Real-world treatment compliance and outcomes in adult patients with localized Ewing sarcoma: A single-institution retrospective study. Medicine (Baltimore). 2025 Jul 18;104(29):e43405. https://doi.org/10.1097/MD.0000000000043405
Thariat J, Italiano A, Peyrade F, Birtwistle-Peyrottes I, Gastaud L, Dassonville O, Thyss A. Very Late Local Relapse of Ewing's Sarcoma of the Head and Neck treated with Aggressive Multimodal Therapy. Sarcoma. 2008;2008:854141. https://doi.org/10.1155/2008/854141
Arafah O, Hegazy RR, Ayadi ME, et al. Prognostic factors and outcome of relapsed/progressive pediatric Ewing sarcoma: single-center 10-year experience. J Egypt Natl Canc Inst. 2024;36:25. https://doi.org/10.1186/s43046-024-00232-4
Kalaci E, Köksoy EB, Akbiyik I, Dursun B, Utkan G. Real-world treatment compliance and outcomes in adult patients with localized Ewing sarcoma: A single-institution retrospective study. Medicine (Baltimore). 2025 Jul 18;104(29):e43405. https://doi.org/10.1097/MD.0000000000043405
Verma V, Denniston KA, Lin CJ, Lin C. A comparison of pediatric vs. adult patients with the Ewing sarcoma family of tumors. Front Oncol. 2017;7:82. https://doi.org/10.3389/fonc.2017.00082
Gupta AA, Pappo A, Saunders N, et al. Clinical outcome of children and adults with localized Ewing sarcoma: impact of chemotherapy dose and timing of local therapy. Cancer. 2010;116:3189–94. https://doi.org/10.1002/cncr.25002
Pretz JL, Barysauskas CM, George S, et al. Localized adult Ewing sarcoma: favorable outcomes with alternating vincristine, doxorubicin, cyclophosphamide, and ifosfamide, etoposide (VDC/IE)-based multimodality therapy. Oncologist. 2017;22:1265–70. https://doi.org/10.1634/theoncologist.2017-0030
Zhang J, Huang Y, Sun Y, et al. Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience. BMC Cancer. 2019;19:1168. https://doi.org/10.1186/s12885-019-6407-5
Gupta N, Dimri K, Garg SK, Arora A, Pandey AK. Real-world data of Ewing sarcoma from a resource-limited setting with poor compliance to treatment leading to poor outcomes. Ecancermedicalscience. 2024;18:1801. https://doi.org/10.3332/ecancer.2024.1801
Stachelek GC, Ligon JA, Vogel J, et al. Predictors of recurrence and patterns of initial failure in localized Ewing sarcoma: a contemporary 20-year experience. Sarcoma. 2021;2021:1–7. https://doi.org/10.1155/2021/6683053
Bal O, Acikgoz Y, Yildiz B, Kos FT, Algin E, Dogan M. Simple and easily accessible prognostic markers in Ewing sarcoma; neutrophil-lymphocyte ratio, neutrophil-platelet score and systemic-inflammation index. J Cancer Res Ther. 2023;19:1241–7. https://doi.org/10.4103/jcrt.jcrt_1496_22
Guven DC, Sahin TK, Erul E, Kilickap S, Gambichler T, Aksoy S. The association between the pan-immune-inflammation value and cancer prognosis: a systematic review and meta-analysis. Cancers (Basel). 2022;14:2675. https://doi.org/10.3390/cancers14112675
Zhao J, Chen R, Zhang Y, Wang Y, Zhu H. Impact of treatment delay on the prognosis of patients with ovarian cancer: A population-based study using the Surveillance, Epidemiology, and End Results Database. J Cancer. 2024;15(2):473-483. https://doi.org/10.7150/jca.87881
Pyeon SY, Han GH, Ki KD, Lee K-B, Lee J-M. Effect of delayed palliative chemotherapy on survival of patients with recurrent ovarian cancer. PLoS One. 2020;15(7):e0236244. https://doi.org/10.1371/journal.pone.0236244
Paoletti X, Lewsley L-A, Daniele G, et al; Gynecologic Cancer InterGroup (GCIG) Meta-analysis Committee. Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(1):e1918939. https://doi.org/10.1001/jamanetworkopen.2019.18939
Donmez D, Evlendi Y, Sahin TK, Barista I, Akin S. Impact of Time-to-Treatment Initiation and First Inter-Cycle Delay in Patients with Hodgkin Lymphoma. J Clin Med. 2025;14(12):4085. https://doi.org/10.3390/jcm14124085
Gunasekaran GH, Hassali MABA, Sabri WMABW, Rahman MTB. Impact of chemotherapy schedule modification on breast cancer patients: a single-centre retrospective study. Int J Clin Pharm. 2020;42(2):642-651. https://doi.org/10.1007/s11096-020-01011-6
Rast M, Fadavi P, Nojomi M, et al. Chemotherapy delays among cancer patients in Iran during the COVID-19 pandemic. BMC Public Health. 2024;24:2299. https://doi.org/10.1186/s12889-024-19780-4
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Sumbal Abbas, Sumera Abdul Karim, Najma Shaheen, Madiha Jameel, Maha Anwar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
